Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of BL-B01D1 versus physician's choice chemotherapy in previously treated unresectable locally advanced, recurrent, or metastatic HR-positive/HER2-negative breast cancer
CTR20241104Phase 3Active
- Sponsor
- Biokin Pharmaceutical
- Start
- May 2024
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of izalontamab brengitecan in breast cancer, sponsored by Biokin Pharmaceutical. Started May 2024; status: active.
02
Drugs
izalontamab brengitecan
03
Conditions
breast cancer
Beyond the preview
Go deeper on CTR20241104.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20241104.